S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Anormed Ord (MM) (ANOR)
Anormed Ord (MM) (ANOR) News

ANOR

Anormed Ord (MM) (ANOR)

Anormed Ord (MM)

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ANOR

1

Date	Time	Source	Headline	Symbol	Company
11/07/2006	3:57PM	PR Newswire (US)	Genzyme Completes Tender Offer for Outstanding Shares of AnorMED	TSXV:ANOR
11/06/2006	11:01PM	PR Newswire (US)	Genzyme and AnorMED Announce Completion of Hart-Scott-Rodino Review	TSXV:ANOR
11/02/2006	11:05PM	PR Newswire (US)	AnorMED Reports Fiscal 2007 Second Quarter Results And An Update On Recent Corporate Events	TSXV:ANOR
11/02/2006	11:05PM	PR Newswire (US)	AnorMED Reports Fiscal 2007 Second Quarter Results And An Update On Recent Corporate Events	TSXV:ANOR
10/26/2006	9:00AM	PR Newswire (US)	Koronis Pharmaceuticals Appoints Stephen Becker, M.D., Chief Medical Officer	NASDAQ:ANOR	Anormed Ord (MM)
10/23/2006	9:00AM	PR Newswire (US)	AnorMED completes enrollment in Phase III trial for MOZOBIL on schedule	TSXV:ANOR
10/17/2006	9:47AM	PR Newswire (US)	AnorMED and Genzyme reach agreement on acquisition	TSXV:ANOR
10/11/2006	9:03PM	PR Newswire (US)	AnorMED has determined Genzyme's offer is a 'superior proposal'	TSXV:ANOR
10/11/2006	8:47PM	PR Newswire (US)	AnorMED has determined Genzyme's offer is a 'superior proposal'	TSXV:ANOR
10/10/2006	11:30PM	PR Newswire (US)	AnorMED announces receipt of proposal from Genzyme Corporation	TSXV:ANOR
10/10/2006	11:30PM	PR Newswire (US)	AnorMED announces receipt of proposal from Genzyme Corporation	TSXV:ANOR
10/10/2006	9:50AM	PR Newswire (US)	Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash	TSXV:ANOR
10/06/2006	11:41AM	PR Newswire (US)	Genzyme Extends Deadline for Tender Offer to Acquire AnorMED Inc.	NASDAQ:ANOR	Anormed Ord (MM)
10/05/2006	10:10PM	PR Newswire (US)	AnorMED Board recommends shareholders accept Millennium offer	TSXV:ANOR
10/05/2006	10:10PM	PR Newswire (US)	AnorMED Board recommends shareholders accept Millennium offer	TSXV:ANOR
10/04/2006	11:36PM	PR Newswire (US)	AnorMED board continues to recommend that shareholders accept Millennium's planned tender offer	TSXV:ANOR
09/26/2006	9:46AM	PR Newswire (US)	Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date	TSXV:ANOR
09/26/2006	9:45AM	PR Newswire (US)	AnorMED agrees to support a planned tender offer of US$12 per share from Millennium Pharmaceuticals	TSXV:ANOR
09/25/2006	12:23AM	PR Newswire (US)	Approval of FOSRENOL in the United Kingdom triggers U.S.$3 million payment to AnorMED	TSXV:ANOR
09/20/2006	9:00AM	PR Newswire (US)	AnorMED reports on Annual General Meeting	TSXV:ANOR
09/19/2006	7:30AM	PR Newswire (US)	AnorMED amends license agreement for cancer drug	TSXV:ANOR
09/19/2006	7:30AM	PR Newswire (US)	Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Cond	TSXV:ANOR
09/18/2006	9:00AM	PR Newswire (US)	Approval of FOSRENOL in Germany triggers U.S.$3 million payment to AnorMED	TSXV:ANOR
09/15/2006	8:22PM	PR Newswire (US)	AnorMED Provides Update on Limited Duration Shareholder Rights Plan	TSXV:ANOR
09/12/2006	12:57PM	PR Newswire (US)	Atticus Capital LP Opposes Genzyme bid for AnorMED	TSXV:ANOR

Showing the most relevant articles for your search:NASDAQ:ANOR

1

NLBNPIT1W544 20241220 50

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions